Cargando…
Intermittent versus Daily Eltrombopag Dosage Protocols for the Treatment of Primary Immune Thrombocytopenia: Real-Life Experience
INTRODUCTION/AIM: Eltrombopag is recommended for the treatment of refractory immune thrombocytopenia (ITP). Based on its half-life, it may be practical to use an intermittent dosage. Our aim was to compare the effectiveness and safety of intermittent vs daily eltrombopag dosage protocols for the tre...
Autores principales: | Elbedewy, Tamer A, Elsebaey, Mohamed A, Elkholy, Reem A, Tahoon, Dina M, Elshweikh, Samah A |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7783199/ https://www.ncbi.nlm.nih.gov/pubmed/33414648 http://dx.doi.org/10.2147/JBM.S289149 |
Ejemplares similares
-
Predictors for eltrombopag response in patients with hepatitis C virus-associated thrombocytopenia
por: Elbedewy, Tamer A, et al.
Publicado: (2019) -
Galectin-3 as a prognostic biomarker for diabetic nephropathy
por: Hodeib, Hossam, et al.
Publicado: (2019) -
Resolved hepatitis B infection in patients receiving immunosuppressive therapy: Monitor versus prophylaxis against viral reactivation
por: Elsebaey, Mohamed A., et al.
Publicado: (2022) -
Eltrombopag in long‐term management of pediatric thrombocytopenia
por: Shah, Sanjay J., et al.
Publicado: (2018) -
Considerations in the Management of Hepatitis C Virus-related Thrombocytopenia with Eltrombopag
por: Danish, Fazal A., et al.
Publicado: (2010)